Pegaspargase

 Drug Class

• Antineoplastic enzyme (asparaginase family).
• PEGylated E. coli–derived L-asparaginase (long-acting form).

Mechanism of Action

• Leukemic lymphoblasts lack asparagine synthetase and depend on circulating asparagine.
• Pegaspargase catalyzes asparagine → aspartic acid + ammonia, depleting plasma asparagine.
• This blocks protein synthesis → apoptosis of leukemic cells.
• Normal cells are less affected since they can synthesize asparagine.
• PEGylation: covalent attachment of polyethylene glycol prolongs half-life, decreases immunogenicity, and allows less frequent dosing compared to native asparaginase.

Indications

• Part of multi-agent chemotherapy for Acute Lymphoblastic Leukemia (ALL).
• FDA approval: Pediatric and adult patients (wider age range than calaspargase).

Dosing

• Typical dose: 2,500 units/m² IV (over 1–2 hours) or IM, every 14 days.
• Max dose: usually capped at 3,750 units.
• Route options: IV (common in practice) or IM (alternative when IV difficult).

Pharmacokinetics

• Half-life: ~5–6 days (longer than native asparaginase but shorter than calaspargase).
• Duration of asparagine depletion: about 2 weeks.
• Less frequent dosing than native asparaginase (which required 3x/week).

Toxicities & Adverse Effects

(class effects of asparaginases)

1. Hypersensitivity / Anaphylaxis
   • Even with PEGylation, reactions occur (less than native E. coli form).
   • Can lead to silent inactivation → reduced efficacy.
   • Infuse with monitoring; switch to Erwinia asparaginase if confirmed allergy.
2. Pancreatitis
   • May be severe (hemorrhagic/necrotizing).
   • Monitor for abdominal pain, ↑ amylase/lipase.
   • Permanently discontinue if ≥Grade 3 pancreatitis.
3. Hepatotoxicity
   • Transaminitis, hyperbilirubinemia, hypoalbuminemia, rare hepatic failure.
   • Monitor LFTs, bilirubin, albumin, coagulation.
4. Thrombosis & Bleeding
   • Decreases antithrombin III, fibrinogen, protein C/S.
   • Risk of VTE, stroke, bleeding.
   • Monitor coagulation; may require AT-III/fibrinogen replacement.
5. Hyperglycemia
   • Due to decreased insulin production (exacerbated by steroids).
6. CNS effects
   • Secondary to thrombosis, metabolic changes.

Monitoring Parameters

• CBC with differential
• LFTs, bilirubin, albumin
• Coagulation profile: PT, aPTT, fibrinogen, AT-III
• Serum glucose
• Amylase/lipase (for pancreatitis)
• Asparaginase activity levels (if institutionally available; target trough ≥0.1 IU/mL)

Clinical Pearls for Practice

• Advantage vs native asparaginase: less frequent dosing (q2w vs 3x/week), lower immunogenicity.
• Advantage vs calaspargase: broader FDA approval (pediatrics & adults), IM option.
• Limitation: shorter half-life than calaspargase → requires q2w dosing.
• Hypersensitivity: always be prepared to manage infusion reactions; switch to Erwinia-derived asparaginase if true PEG allergy.
• Supportive care: thromboembolic prophylaxis not routine but consider in high-risk ALL patients; treat coagulopathies symptomatically.

Key Point for Oncology Pharmacist:

Pegaspargase is a long-acting PEGylated asparaginase used in ALL protocols, typically q2w IV/IM, with major toxicities being hypersensitivity, pancreatitis, hepatotoxicity, and thrombosis/bleeding. Close laboratory monitoring and vigilance for toxicity are essential.